Expertise in
17
conditions

Dr. Stavroula A. Otis

Hematology Oncology
363 South Main Street, Suite 485, 
Orange, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
17
conditions
363 South Main Street, Suite 485, 
Orange, CA 

Overview

Stavroula Otis is a Hematologist Oncology provider practicing medicine in Orange, California.

Dr. Otis is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Prostate Cancer.

She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 5 clinical trials. Dr. Otis is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Providence St. Joseph Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

363 South Main Street, Suite 485, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

1 Total Publications

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2013
Similar Doctors
Expertise in
35
conditions
Dr. Timothy E. Byun
Hematology Oncology
Expertise in
35
conditions
Dr. Timothy E. Byun
Hematology Oncology
Referral may be required
Before you request
1010 West La Veta Avenue, Suite 200, 
Orange, CA 
 (0.1 miles away)
714-541-6622
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Byun is a Hematologist Oncology provider practicing medicine in Orange, California. Dr. Byun is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Anal Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Byun is currently accepting new patients.

Expertise in
48
conditions
Dr. David J. Park
Hematology Oncology
Expertise in
48
conditions
Dr. David J. Park
Hematology Oncology
Referral may be required
Before you request
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 
 (8.2 miles away)
714-446-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Park is a Hematologist Oncology provider practicing medicine in Fullerton, California. Dr. Park is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Park is currently accepting new patients.

Expertise in
16
conditions
Dr. Yung Lyou
Hematology Oncology | Oncology
Expertise in
16
conditions
Dr. Yung Lyou
Hematology Oncology | Oncology
Referral may be required
Before you request
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 
 (8.2 miles away)
714-446-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yung Lyou is a Hematologist Oncology specialist and an Oncologist practicing medicine in Fullerton, California. Dr. Lyou is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Hormone Replacement Therapy (HRT). Dr. Lyou is currently accepting new patients.

Frequently Asked Questions about Dr. Stavroula A. Otis

How do I make an appointment with Dr. Stavroula A. Otis?

You can book an appointment with Dr. Stavroula A. Otis by calling their office at 714-835-4800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stavroula A. Otis a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stavroula A. Otis is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stavroula A. Otis specialize in?

While Dr. Stavroula A. Otis is a Hematology Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Stavroula A. Otis participate in research or clinical trials?

Yes. Dr. Stavroula A. Otis has published 1 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Stavroula A. Otis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stavroula A. Otis accept my insurance?

Dr. Stavroula A. Otis accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-835-4800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Otis's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile